Zoloft (Sertraline) and Glaucoma Risk: What You Need to Know

Understanding Sertraline and Glaucoma: Separating Fact from Fiction

If you're taking Zoloft (sertraline) or considering this medication, you may have heard concerns about its potential effects on eye health, particularly glaucoma: which means nerve damage and can be potentially blinding if not treated early. 

Let's examine what the scientific evidence actually tells us about this relationship and explore which medications truly pose risks for glaucoma patients.

Does Sertraline Increase Glaucoma Risk?

The relationship between sertraline and other selective serotonin reuptake inhibitors (SSRIs) and glaucoma remains controversial, with research showing mixed results.[1][2]

A large Taiwanese population study of over 15,000 glaucoma cases found that SSRI use was associated with a modestly increased risk of glaucoma (adjusted odds ratio 1.09), particularly with longer duration of treatment (>365 days) and higher doses.[1] However, this association was relatively weak and limited to certain patient populations—specifically those younger than 65 years without diabetes, hypertension, or high cholesterol.[1]

In contrast, a comprehensive meta-analysis of over 801,000 participants found no significant association between SSRI use and increased glaucoma risk (pooled adjusted odds ratio 0.956).[2] Interestingly, this same analysis found that SSRIs were actually associated with lower intraocular pressure and larger pupil diameter.[2] A more recent Bayesian meta-analysis of 293,228 psychotropic medication users confirmed that SSRIs were associated with a modestly reduced risk of open-angle glaucoma and lower intraocular pressure.[3]

The FDA label for sertraline does include a warning about angle-closure glaucoma, noting that "the pupillary dilation that occurs following use of many antidepressant drugs, including sertraline hydrochloride, may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy." The label recommends avoiding sertraline in patients with untreated anatomically narrow angles.[4] The red angle in the below photo represents the drain inside the eye where the cornea meets the iris which can get narrow in patients that are developing a cataract.

Once the cataract is removed, there is an almost 0 risk of angle closure Glaucoma from medications assuming the surgery went well, and the patient doesn’t have a secondary condition. 

Analysis of the FDA Adverse Event Reporting System revealed that among SSRIs, citalopram showed the highest association with angle-closure glaucoma reports, while sertraline was not specifically highlighted as having elevated risk.[5] Most SSRI-related eye disorders occurred within the first 30 days of treatment.[5]

How SSRIs Might Affect the Eyes

SSRIs can influence eye structures through several mechanisms:[6]

Pupillary dilation (mydriasis): SSRIs affect pupil size through serotonergic mechanisms, which can theoretically trigger angle closure in patients with anatomically narrow angles.[2][6] When the pupil dilates, it can cause the iris to bunch up and block the drainage angle where fluid exits the eye, leading to a rapid increase in intraocular pressure.[6]

Anticholinergic effects: Some SSRIs have mild anticholinergic properties that can contribute to pupil dilation.[6]

However, it's important to note that the overall evidence suggests SSRIs may actually lower intraocular pressure rather than raise it, which would be protective against glaucoma.[2][3]

The Protective Effect of Cataract Surgery on Angle-Closure Risk

An important consideration for patients concerned about angle-closure glaucoma is that cataract surgery dramatically reduces the risk of angle closure by fundamentally changing the anatomy of the eye.[7][8]

How cataract surgery protects against angle closure: The natural lens of the eye thickens with age, taking up more space in the front of the eye and contributing to angle crowding. During cataract surgery, this enlarged natural lens is removed and replaced with a much thinner artificial lens implant, creating significantly more space within the anterior chamber of the eye.[7] This allows aqueous humor (the fluid inside the eye) to drain normally through the angle between the iris and cornea.[7]

Evidence of angle widening: Multiple studies using ultrasound biomicroscopy have documented that cataract surgery significantly widens the anterior chamber angle in eyes with angle-closure disease.[8][9] One study found that not only did the anterior chamber depth and angle opening distance increase after cataract surgery, but the positioning of the ciliary processes also moved backward, all contributing to sustained angle widening.[9]

Clinical effectiveness: The landmark EAGLE (Effectiveness in Angle-closure Glaucoma of Lens Extraction) trial demonstrated that clear lens extraction was superior to laser peripheral iridotomy for controlling intraocular pressure in patients with angle closure, with better quality of life outcomes.[7][8][10] Studies across the spectrum of angle-closure disease—from angle-closure suspects to advanced glaucoma—have shown significant and sustained reductions in intraocular pressure following cataract surgery alone.[11]

Important clarification: While cataract surgery dramatically reduces the anatomical risk factors for angle closure by removing the enlarged lens and widening the anterior chamber angle, patients who have undergone cataract surgery should still be aware that they need ongoing eye care. The surgery addresses the primary mechanism of pupillary block angle closure, making medication-induced angle closure extremely unlikely in pseudophakic eyes (eyes with artificial lens implants).[7][8]

For patients with narrow angles who require medications that could potentially trigger angle closure (such as anticholinergics or topiramate), prior cataract surgery provides substantial protection by eliminating the anatomical crowding that makes angle closure possible.[7][8]

Medications That Worsen Glaucoma: The Real Culprits

While the evidence for SSRIs remains mixed, several other medication classes have stronger associations with glaucoma:

1. Corticosteroids (Strong Evidence)

Corticosteroids are among the most well-established causes of drug-induced glaucoma.[12] All formulations—including oral, inhaled, intravenous, topical, and eye drops—can elevate intraocular pressure and increase glaucoma risk.[12] The risk increases with higher steroid strength, longer exposure, and closer proximity of administration to the eye.[12]

Why they cause problems: Corticosteroids alter the trabecular meshwork (the eye's drainage system), reducing aqueous humor outflow and increasing intraocular pressure.[12]

2. Topiramate (Very Strong Evidence)

Topiramate, an anticonvulsant also used for migraine prevention and weight loss, has one of the strongest associations with acute angle-closure glaucoma, with an odds ratio of 5.10 in one large study and 3.93 in a recent meta-analysis.[3][13]

Why it causes problems: Unlike most drugs that cause angle closure through pupil dilation, topiramate works through an entirely different mechanism. It causes ciliary body edema and uveal effusion, leading to forward displacement of the lens-iris diaphragm and closure of the drainage angle.[6][14]

3. Anticholinergic Medications (Strong Evidence)

Medications with anticholinergic properties pose significant risks for angle-closure glaucoma:[12]

- Tricyclic antidepressants

- Antihistamines

- Antiparkinsonian medications

- Antipsychotics with anticholinergic properties

- Overactive bladder medications (propiverine, solifenacin)

- Botulinum toxin

Why they cause problems: Anticholinergics cause pupil dilation (mydriasis), which can lead to pupillary block in susceptible patients. The dilated pupil allows aqueous humor to build up in the posterior chamber, pushing the iris forward and closing the drainage angle.[12]

4. Benzodiazepines (Moderate Evidence)

A recent meta-analysis found that benzodiazepines were associated with significantly increased glaucoma risk (odds ratio 1.55), with consistent effects across both short- and long-acting compounds.[3]

Why they cause problems: The exact mechanism is not fully understood but may involve effects on pupil configuration and anterior chamber dynamics.[3]

5. Sulfonamide Antibiotics and Diuretics (Moderate Evidence)

Sulfonamide-containing medications can precipitate angle closure through a mechanism similar to topiramate.[14][12]

Why they cause problems: These medications cause supraciliary effusions with forward rotation of the iris-lens diaphragm, closing the drainage angle.[12]

6. Adrenergic Agonists (Moderate Evidence)

Medications that stimulate adrenergic receptors, including decongestants and certain asthma medications, can trigger angle closure.[12][15]

Why they cause problems: Adrenergic stimulation causes pupil dilation, which can precipitate angle closure in susceptible individuals.[12]

7. Calcium Channel Blockers (Emerging Evidence)

A large European study found that calcium channel blocker use was associated with higher glaucoma prevalence (odds ratio 1.23), particularly for medications with direct cardiac effects (odds ratio 1.96).[16]

Why they cause problems: The mechanism is not fully understood but may involve effects on ocular blood flow or trabecular meshwork function.[16]

8. Other Medications Associated with Acute Angle Closure

A comprehensive Korean study identified 61 medications associated with acute angle closure, including:[13]

- Sumatriptan (migraine medication) - highest odds ratio of 12.60

- Duloxetine (SNRI antidepressant) - odds ratio of 4.04

- Antiemetics (metoclopramide, dimenhydrinate)

- H2 blockers (cimetidine, ranitidine)

- Laxatives (lactulose)

- NSAIDs (mefenamic acid, aspirin)

Who Is at Highest Risk?

Not everyone who takes these medications will develop glaucoma. The highest-risk individuals include:[6]

- People with anatomically narrow angles (more common in those with hyperopia/farsightedness)

- Older adults

- Individuals of Asian descent

- Those with a family history of glaucoma

- People with certain eye anatomies (shallow anterior chamber, thick lens)

Important note: Patients who have undergone cataract surgery have substantially reduced anatomical risk for angle-closure glaucoma because the enlarged natural lens—the primary cause of angle crowding—has been removed and replaced with a thinner artificial lens.[7][8]

What Should You Do?

If you're taking sertraline or another SSRI: The overall evidence suggests that SSRIs, including sertraline, do not significantly increase glaucoma risk for most people and may even have protective effects on intraocular pressure.[2][3] However, if you have anatomically narrow angles or other risk factors, discuss this with your healthcare provider.[4]

If you have narrow angles and need cataract surgery: Cataract surgery is now recognized as a highly effective treatment for angle-closure disease and may be recommended even before cataracts become visually significant if you have angle closure with elevated intraocular pressure.[7][8][10] The EAGLE trial showed that early lens extraction provided better pressure control and quality of life than traditional laser treatment.[7][8]

If you've had cataract surgery: The removal of your natural lens and replacement with a thinner artificial lens has fundamentally changed your eye anatomy, dramatically reducing your risk of angle-closure glaucoma.[7][8] This provides substantial protection if you need to take medications that could potentially affect pupil size.

If you're taking high-risk medications: If you need to take medications known to increase glaucoma risk (especially topiramate, anticholinergics, or long-term corticosteroids), consider:[12]

- Eye examination before starting the medication to assess your angle anatomy

- Prophylactic laser peripheral iridotomy if you have narrow angles

- Discussion with your ophthalmologist about whether early cataract surgery might be appropriate if you have narrow angles

- Regular monitoring of intraocular pressure

- Education about symptoms of acute angle closure (severe eye pain, blurred vision, halos around lights, nausea)

Know the warning signs of acute angle closure:[12]

- Severe eye pain

- Sudden vision changes or blurred vision

- Seeing halos around lights

- Red eye

- Nausea and vomiting

If you experience these symptoms, seek immediate emergency eye care, as acute angle-closure glaucoma can cause permanent vision loss within hours if untreated.[12]

The Bottom Line

While sertraline's FDA label includes a warning about angle-closure glaucoma, the overall scientific evidence does not support a strong association between SSRIs and increased glaucoma risk. In fact, SSRIs may lower intraocular pressure. The medications with the strongest evidence for worsening glaucoma include corticosteroids, topiramate, anticholinergics, and benzodiazepines.

An important protective factor is cataract surgery, which dramatically reduces the risk of angle-closure glaucoma by removing the enlarged natural lens and replacing it with a thinner artificial lens, fundamentally widening the anterior chamber angle.[7][8] For patients with narrow angles who require medications that could affect pupil size, cataract surgery provides substantial anatomical protection against angle closure.

If you have risk factors for glaucoma or are taking high-risk medications, work with both your prescribing physician and an eye care professional to monitor your eye health appropriately.

The updated blog post now includes a comprehensive section on how cataract surgery affects angle-closure risk, supported by evidence from landmark trials like EAGLE and multiple studies documenting anatomical changes after lens extraction.[7][8][10][11][9]

The evidence shows that cataract surgery dramatically reduces the risk of angle-closure glaucoma by removing the enlarged natural lens (which is the primary cause of angle crowding) and replacing it with a much thinner artificial lens implant.[7][8] This creates significantly more space in the anterior chamber and widens the drainage angle.[8][9] The American Academy of Ophthalmology guidelines note that lens extraction "significantly widens the anterior chamber angle" and is now considered superior to laser treatment for many patients with angle-closure disease.[8]

However, it's important to note that the medical literature does not support the claim that the risk becomes "zero" after cataract surgery. While the surgery addresses the primary anatomical mechanism of pupillary block angle closure and provides substantial protection, the evidence demonstrates risk reduction rather than complete elimination. The research shows sustained angle widening and improved intraocular pressure control, making medication-induced angle closure extremely unlikely in eyes with artificial lens implants, but does not establish absolute zero risk.[7][8][10]

References

1. Effects of Selective Serotonin Reuptake Inhibitors on Glaucoma: A Nationwide Population-Based Study. Chen VC, Ng MH, Chiu WC, et al. PloS One. 2017;12(3):e0173005. doi:10.1371/journal.pone.0173005.

2. The Risk of Glaucoma and Serotonergic Antidepressants: A Systematic Review and Meta-Analysis. Wang HY, Tseng PT, Stubbs B, et al. Journal of Affective Disorders. 2018;241:63-70. doi:10.1016/j.jad.2018.07.079.

3. The Effect of Psychotropic Medications on Glaucoma Risk and Intraocular Pressure: A Bayesian Meta-Analysis. Jannini TB, Alisi L, Giovannetti F, et al. CNS Drugs. 2025;:10.1007/s40263-025-01249-6. doi:10.1007/s40263-025-01249-6.

4. sertraline hydrochloride. Food and Drug Administration. Updated date: 2025-08-06.

5. Eye Disorders Associated With Selective Serotonin Reuptake Inhibitors: A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System. Li J, Zhong R, Guo Y, Zhang F. Expert Opinion on Drug Safety. 2025;24(7):853-863. doi:10.1080/14740338.2024.2385497.

6. Psychotropic Drug-Induced Glaucoma: A Practical Guide to Diagnosis and Management. Jain NS, Ruan CW, Dhanji SR, Symes RJ. CNS Drugs. 2021;35(3):283-289. doi:10.1007/s40263-020-00790-w.

7. Glaucoma: Now and Beyond. Jayaram H, Kolko M, Friedman DS, Gazzard G. Lancet (London, England). 2023;402(10414):1788-1801. doi:10.1016/S0140-6736(23)01289-8.

8. Primary Angle-Closure Disease Preferred Practice Pattern®. Gedde SJ, Chen PP, Muir KW, et al. Ophthalmology. 2021;128(1):P30-P70. doi:10.1016/j.ophtha.2020.10.021.

9. Angle Widening and Alteration of Ciliary Process Configuration After Cataract Surgery for Primary Angle Closure. Nonaka A, Kondo T, Kikuchi M, et al. Ophthalmology. 2006;113(3):437-41. doi:10.1016/j.ophtha.2005.11.018.

10. Cataract Surgery and Intraocular Pressure in Glaucoma. Young CEC, Seibold LK, Kahook MY. Current Opinion in Ophthalmology. 2020;31(1):15-22. doi:10.1097/ICU.0000000000000623.

11. Intraocular Pressure Reduction in a Spectrum of Angle Closure Disease Following Cataract Extraction. Pandav SS, Seth NG, Arora A, et al. Indian Journal of Ophthalmology. 2019;67(9):1433-1438. doi:10.4103/ijo.IJO_1917_18.

12. Glaucoma in Adults—Screening, Diagnosis, and Management: A Review. Stein JD, Khawaja AP, Weizer JS. JAMA. 2021;325(2):164-174. doi:10.1001/jama.2020.21899.

13. Association of Drugs With Acute Angle Closure. Na KI, Park SP. JAMA Ophthalmology. 2022;140(11):1055-1063. doi:10.1001/jamaophthalmol.2022.3723.

14. Glaucoma: Diagnosis and Management. Michels TC, Ivan O. American Family Physician. 2023;107(3):253-262.

15. A Review of Systemic Medications That May Modulate the Risk of Glaucoma. Wu A, Khawaja AP, Pasquale LR, Stein JD. Eye (London, England). 2020;34(1):12-28. doi:10.1038/s41433-019-0603-z.

16. Association of Systemic Medication Use With Glaucoma and Intraocular Pressure: The European Eye Epidemiology Consortium. Vergroesen JE, Schuster AK, Stuart KV, et al. Ophthalmology. 2023;130(9):893-906. doi:10.1016/j.ophtha.2023.05.001.